Margin pressure from MR expansion
Employee costs remain high due to addition of 600 MRs over three years; margins may take time to reach peer levels.
medium · analyst_questionCORONA Remedies Limited — Q3 FY26
Corona Remedies delivered a strong Q3 FY26 with revenue of ₹342 crore (+15% YoY), EBITDA of ₹83 crore (+20% YoY), and adjusted PAT of ₹56 crore (+24% YoY).
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Q4 margin seasonality from new launches
Management acknowledged possible higher distribution costs in Q4 due to GLP-1 launch, which could compress margins.
medium · management_commentaryExecution risk in IVF portfolio ramp-up
The IVF portfolio from Bayer requires cold chain management and specialist detailing; success depends on adoption by 3,000 centers.
medium · analyst_questionInorganic acquisition uncertainty
Management is evaluating two brand acquisitions but noted low conversion probability, leaving growth partly dependent on organic efforts.
low · management_commentary